Guggenheim maintains buy rating on Roivant Sciences stock amid DM study

Published 18/06/2025, 11:56
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study

Guggenheim has reiterated a Buy rating and $15.00 price target on Roivant Sciences (NASDAQ:ROIV), currently trading at $11.11, following the company’s webinar on brepocitinib development in dermatomyositis (DM). According to InvestingPro data, analyst targets range from $12 to $22, suggesting significant upside potential, though the stock appears slightly overvalued at current levels.

The webinar, held Monday, focused on the company’s JAK1/TYK2 dual inhibitor and its ongoing Phase III VALOR study, which includes 241 patients and is expected to report results in the second half of 2025.

Dermatomyositis affects approximately 40,000-50,000 U.S. patients and is described as a debilitating disease that remains poorly controlled with standard-of-care treatments, despite the use of heavy steroids, immunosuppressants, and off-label JAK inhibitors.

Guggenheim noted that increasing use of JAK inhibitors, including three investigator-initiated trials and over 600 published cases, along with efficacy signals from trials of tofacitinib and ustekinumab, provide indirect support for brepocitinib’s mechanism of action in DM.

The research firm believes Roivant Sciences has taken appropriate steps to manage the high placebo response typically seen in this indication, and estimates the drug could generate more than $1 billion in sales for dermatomyositis if approved.

In other recent news, Roivant Sciences has been in the spotlight with several significant developments. The company reported positive Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension, showing it was well tolerated with no major side effects. This promising data supports ongoing Phase 2 trials for the drug. In another update, H.C. Wainwright reaffirmed its Buy rating and $18 price target for Roivant Sciences, citing the company’s strategic focus on expanding its therapeutic areas and a strong financial position. Additionally, Cantor Fitzgerald maintained an Overweight rating, highlighting Roivant’s decision to concentrate on fewer indications for its IMVT-1402 therapy, which could enhance development efficiency.

Roivant Sciences also announced a management change at its subsidiary, Immunovant (NASDAQ:IMVT), with Eric Venker taking over as CEO. This leadership shift aligns with the company’s strategy to focus on new therapeutic areas, including Sjogren’s syndrome and cutaneous lupus erythematosus. In corporate governance news, Roivant finalized a consulting agreement with its former Chief Accounting Officer, Rakhi Kumar, to provide advisory services during a transition period. This agreement allows the company to leverage her expertise while she continues to vest in her equity awards. These recent developments reflect Roivant Sciences’ ongoing efforts to advance its pipeline and streamline its operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.